Publications

In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. by Gales AC, Jones RN, Andrade SS, Pereira AS and Sader HS published in Braz. J. Infect. Dis. 2005; 9 (5): 348-356

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. by Streit, J.M., Sader, H.S., Fritsche, T.R., Jones, R.N. published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 307-310

Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American Medical Centers (2003). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 329-332

An overview of the Meropenem Yearly Susceptibility Test Information Collection (Mystic) Program: 1997-2004. by Jones RN, Mendes C, Turner PJ and Masterton R published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 247-256

Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. by Jones RN, Fritsche TR, Ge Y, Kaniga K and Sader HS published in J. Antimicrob. Chemother. 2005; 56 (6): 1047-1052

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. by Jones RN, Critchley IA, Whittington WL, Janjic N and Pottumarthy S published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 311-317

Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. by Ross JE and Jones RN published in J. Clin. Microbiol. 2005; 43 (12): 6212-6213

Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed rormulations and pharmacookinetic relationships: Do the MIC obtained with 2:1 ratio testing accurately reflect activity against β-lactamase-producing strains of Haemophilus Influenzae and Moraxella Catarrhalis? by Pottumarthy, S, Sader, HS, Fritsche, TR, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2005; 53 (3): 225-231

Broth microdilution susceptibility testing of Campylobacter jejuni and the determination of quality control ranges for fourteen antimicrobial agents. by McDermott PF, Bodeis-Jones SM, Fritsche TR, Jones RN, Walker RD andCampylobacter Susceptibility Testing Group T. published in J. Clin. Microbiol. 2005; 43 (12): 6136-6138

Antimicrobial susceptibility patterns of unusual nonfermentative Gram-negative bacilli isolated from Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2002). by Gales AC, Jones RN, Andrade SS and Sader HS published in Mem. Inst. Oswaldo Cruz 2005; 100 (6): 571-577

Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). by Fritsche TR, Stilwell MG and Jones RN published in Clin. Microbiol. Infect. 2005; 11 (12): 974-984

Importance of understanding pharmacokinetic/pharmocodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus. by Fritsche TR and Jones RN published in J. Drugs Dermatol. 2005; 4 (Suppl 6): s4-s8

Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan. by Wu LT, Hung SW, Chuang YC, Chen HE, Jones RN and Yu WL published in Clin. Microbiol. Inf. 2005; 11 (11): 893-897

Susceptibility testing accuracy of a CTX-M-type extended-spectrum ß-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 ß-lactams. by Pottumarthy S, Yu Y, Sader HS, Jones RN and Chen M published in Diagn. Microbiol. Infect. Dis. 2005; 53 (2): 131-141

The SENTRY Asia-Pacific participants: Regional variation in the prevalence of extended-spectrum ß-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). by Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, Ono Y, Nakazaki N, Hirata Y, Inoue M, Turnidge JD, Bell JM, Jones RN and Kohno S published in Diagn. Microbiol. Infect. Dis. 2005; 52 (4): 323-329

Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from six continents. by Sader HS, Jones RN, Stilwell MG, Dowzicky MJ and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 181-186

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. by Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 187-193

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000 – 2004). by Fritsche, TR, Sader HS, Stilwell MG, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 195-201

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. by Sader HS, Jones RN, Dowzicky MJ and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3):203-208

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. by Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3):209-213

Re-evaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for bine beta-lactams: Adjustments of breakpoints for strains producing extended-spectrum beta-lactamases. by Jones, R.N., Craig, W.A., Ambrose, P.G., Dudley, M.N., Pottumarthy, S. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 235-246

Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998 – 2003). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 265-273

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. by Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN published in Antimicrob. Agents Chemother. 2005; 49 (8): 3501-3512

Emerging metallo-b-lactamase-mediated resistances: A summary report from the worldwide SENTRY Antimicrobial Surveillance Program. by Fritsche TR, Sader HS, Toleman MA, Walsh TR and Jones RN published in Clin. Infect. Dis. 2005; 41 (Suppl 4): S276-S278

Trends in linezolid susceptibility patterns: Report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. by Anderegg TR, Sader HS, Fritsche TR, Ross JE and Jones RN published in Int. J. Antimicrob. Agents 2005; 26 (1): 13-21

Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 129-133

Re-evaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms. by Pottumarthy S, Deshpande LM, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 95-99

Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. by Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN and Ambrose PG published in Antimicrob. Agents Chemother. 2005; 49 (5): 1775-1781

Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. by Ross JE, Anderegg TR, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 53-58

Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 67-69

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. by Jones, R.N., Sader, H.S., Fritsche, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 71-74

Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. by Stelling JM, Travers K, Jones RN, Turner PJ, O’Brien TF and Levy SB published in Emerg. Infect. Dis. 2005; 11 (6): 873-882

Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multidrug resistant Pseudomonas aeruginosa and Acinetobacter spp. by Sader, H.S., Jones, R.N. published in Int. J. Antimicrob. Agents. 2005; 25 (5):380-384

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. by Streit, J.M., Steenbergen, J.N., Thorne, G.M., Alder, J., Jones, R.N. published in J. Antimicrob. Chemother. 2005; 55 (4): 574-578

Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels. by Ross JE, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (3): 219-221

Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002 – 2003): Contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. by Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (4): 282-289

Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. by Bell JA, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y and Jones RN published in J. Antimicrob. Chemother. 2005; 55 (2):276-278

Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. by Fritsche, TR, Sader, HS, Cleeland, R, Jones, RN published in Antimicrob. Agents Chemother. 2005; 49 (4): 1468-147

Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. by Rhomberg PR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (3): 274-276

Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. by Jones RN, Anderegg TR and Swenson JM published in J. Clin. Microbiol. 2005; 43 (2): 925-927

Italian metallo-β-lactamases: A national problem? Report from the SENTRY Antimicrobial Surveillance Programme. by Toleman, M.A., Biedenbach, D., Bennett, D.M.C., Jones, R.N., Walsh, T.R published in J. Antimicrob. Chemother. 2005; 55 (1): 61-70

Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: Report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003). by Pottumarthy, S., Fritsche, T.R., Jones, R.N. published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 147-150

Emerging epidemic of metallo-β-lactamase-mediated resistances. by Jones, R.N., Biedenbach, D.J., Sader, H.S., Fritsche, T.R., Toleman, M.A., Walsh, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 77-84

Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). by Jones RN, Sader HS and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 139-141

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American Medical Centres. by Gales AC, Sader HS, Jones RN published in Clin. Microbiol. Infect. 2005; 11 (2): 95-100

Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. by Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (2):95-109

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. by Bhavnani SM, Hammel JP, Jones RN and Ambrose PG published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1): 31-37

Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003). by DiPersio JR, Deshpande LM, Biedenbach DJ, Toleman MA, Walsh TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1): 1-7

Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: Validation report from the SENTRY Antimicrobial Surveillance Program. by Pottumarthy S, Fritsche TR, Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1):57-62

Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. by Sader HS, Biedenbach DJ, Streit JM and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (1): 89-92